NEW YORK (GenomeWeb) – Admera Health and the University of Rochester School of Medicine and Dentistry announced today that they have begun enrollment in a clinical study evaluating the use of the company's 50-gene PGxOne Plus pharmacogenomics test in guiding pain management decisions following acute dental surgery.
PGxOne Plus uses next-generation sequencing technology to interrogate genes in order to predict how patients will respond to drug therapy. Reports sent to clinicians include information on whether specific drugs should be avoided, alternative treatments, and dosage adjustments.
The partners specifically aim to see if preoperative use of the test can significantly improve the efficacy of surgical pain management, as well as characterize the association between gene-drug interactions and clinical outcomes. The university will provide patient samples to Admera for analysis.
Additional terms of the deal were not disclosed.
"Most acute surgical pain methods have shown inconsistent effects on pain relief and rely excessively on opioid use, which has associated dependency issues," Admera President and CEO Guanghui Hu said in a statement. "With the implementation of our PGxOne Plus test, we are confident that this study will demonstrate improved patient outcomes, similar to the way pharmacogenomics has been clinically validated in other therapeutic areas."